While the American Diabetes Association Guidelines recommend incretin-based pharmacotherapy for patients with type 2 diabetes irrespective of baseline weight, only four studies examining GLP-1 RA and/or GLP-1/GIP RA efficacy in patients of normal weight or underweight in any capacity were identified. This evidence concerns the gene GIP and diabetes mellitus.